+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pancreatic Cancer - Pipeline Review, H2 2018

  • ID: 4726722
  • Drug Pipelines
  • December 2018
  • Region: Global
  • 2787 Pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • Allinky Biopharma SL
  • ArQule Inc
  • Biokine Therapeutics Ltd
  • CCRP Therapeutics GmbH
  • CytImmune Sciences Inc
  • MORE

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H2 2018, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of the skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

This latest pipeline guide Pancreatic Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in the therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 20, 165, 153, 3, 8, 296, 39 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 20, 10, 2, 1, 56 and 8 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective counter-strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real-time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on a mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with the potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • Allinky Biopharma SL
  • ArQule Inc
  • Biokine Therapeutics Ltd
  • CCRP Therapeutics GmbH
  • CytImmune Sciences Inc
  • MORE
  • Introduction
  • Pancreatic Cancer - Overview
  • Pancreatic Cancer - Therapeutics Development
  • Pancreatic Cancer - Therapeutics Assessment
  • Pancreatic Cancer - Companies Involved in Therapeutics Development
  • Pancreatic Cancer - Drug Profiles
  • Pancreatic Cancer - Dormant Projects
  • Pancreatic Cancer - Discontinued Products
  • Pancreatic Cancer - Product Development Milestones
  • Appendix

List of Tables
Number of Products under Development for Pancreatic Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pancreatic Cancer - Pipeline by 3-V Biosciences Inc, H2 2018
Pancreatic Cancer - Pipeline by 4P-Pharma SAS, H2 2018
Pancreatic Cancer - Pipeline by 4SC AG, H2 2018
Pancreatic Cancer - Pipeline by AB Science SA, H2 2018
Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2018
Pancreatic Cancer - Pipeline by AbGenomics International Inc, H2 2018
Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2018
Pancreatic Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2018
Pancreatic Cancer - Pipeline by Actuate Therapeutics Inc, H2 2018
Pancreatic Cancer - Pipeline by Adamed Sp z oo, H2 2018
Pancreatic Cancer - Pipeline by ADC Therapeutics SA, H2 2018
Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H2 2018
Pancreatic Cancer - Pipeline by Advanced BioDesign, H2 2018
Pancreatic Cancer - Pipeline by Advantagene Inc, H2 2018
Pancreatic Cancer - Pipeline by Advanz Pharmaceutical Corp , H2 2018
Pancreatic Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018
Pancreatic Cancer - Pipeline by Agency for Science, Technology and Research, H2 2018
Pancreatic Cancer - Pipeline by AGV Discovery SAS, H2 2018
Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H2 2018
Pancreatic Cancer - Pipeline by Alissa Pharma, H2 2018
Pancreatic Cancer - Pipeline by Alligator Bioscience AB, H2 2018
Pancreatic Cancer - Pipeline by Allinky Biopharma SL, H2 2018
Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H2 2018
Pancreatic Cancer - Pipeline by Altor BioScience Corp, H2 2018
Pancreatic Cancer - Pipeline by ALX Oncology Inc, H2 2018
Pancreatic Cancer - Pipeline by Ambrx Inc, H2 2018
Pancreatic Cancer - Pipeline by amcure GmbH, H2 2018
Pancreatic Cancer - Pipeline by Amgen Inc, H2 2018
Pancreatic Cancer - Pipeline by Amplia Therapeutics Ltd, H2 2018
Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H2 2018
Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2018
Pancreatic Cancer - Pipeline by ANP Technologies Inc, H2 2018
Pancreatic Cancer - Pipeline by AntiCancer Inc, H2 2018
Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2018
Pancreatic Cancer - Pipeline by Apexigen Inc, H2 2018
Pancreatic Cancer - Pipeline by Aphios Corp, H2 2018
Pancreatic Cancer - Pipeline by Aposense Ltd, H2 2018
Pancreatic Cancer - Pipeline by Aravive Inc, H2 2018
Pancreatic Cancer - Pipeline by ArQule Inc, H2 2018
Pancreatic Cancer - Pipeline by Array BioPharma Inc, H2 2018

List of Figures
Number of Products under Development for Pancreatic Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 3-V Biosciences Inc
  • 4P-Pharma SAS
  • 4SC AG
  • AB Science SA
  • AbbVie Inc
  • AbGenomics International Inc
  • Ability Pharmaceuticals SL
  • Aclaris Therapeutics Inc
  • Actuate Therapeutics Inc
  • Adamed Sp z oo
  • ADC Therapeutics SA
  • Aduro BioTech Inc
  • Advanced BioDesign
  • Advantagene Inc
  • Advanz Pharmaceutical Corp
  • Advenchen Laboratories LLC
  • Agency for Science, Technology and Research
  • AGV Discovery SAS
  • AIMM Therapeutics BV
  • Alissa Pharma
  • Alligator Bioscience AB
  • Allinky Biopharma SL
  • Almac Discovery Ltd
  • Altor BioScience Corp
  • ALX Oncology Inc
  • Ambrx Inc
  • amcure GmbH
  • Amgen Inc
  • Amplia Therapeutics Ltd
  • Anavex Life Sciences Corp
  • Andarix Pharmaceuticals Inc
  • ANP Technologies Inc
  • AntiCancer Inc
  • APEIRON Biologics AG
  • Apexigen Inc
  • Aphios Corp
  • Aposense Ltd
  • Aravive Inc
  • ArQule Inc
  • Array BioPharma Inc
  • Asana BioSciences LLC
  • Ascelia Pharma AB
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Ltd
  • AVEO Pharmaceuticals Inc
  • Axcentua Pharmaceuticals AB
  • Basilea Pharmaceutica Ltd
  • Batu Biologics Inc
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Bellicum Pharmaceuticals Inc
  • Berg LLC
  • BerGenBio ASA
  • Bexion Pharmaceuticals LLC
  • BeyondSpring Inc
  • Bio-Path Holdings Inc
  • BioAtla LLC
  • Biokine Therapeutics Ltd
  • BioLineRx Ltd
  • BioMoti Ltd
  • Biomunex Pharmaceuticals
  • Biothera Pharmaceutical Inc
  • Biouniversa srl
  • BioXcel Therapeutics Inc
  • BLR Bio LLC
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • BriaCell Therapeutics Corp
  • Bristol-Myers Squibb Co
  • Cancer Prevention Pharmaceuticals Inc
  • Canget BioTekpharma LLC
  • Cantargia AB
  • Cantex Pharmaceuticals Inc
  • CARsgen Therapeutics Ltd
  • CBM BioPharma Inc
  • CBT Pharmaceuticals Inc
  • CCRP Therapeutics GmbH
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Celleron Therapeutics Ltd
  • Cellular Biomedicine Group Inc
  • Celprogen Inc
  • Celyad SA
  • Centrose LLC
  • ChemoCentryx Inc
  • Chugai Pharmaceutical Co Ltd
  • Clovis Oncology Inc
  • COARE Biotechnology Inc
  • Codiak BioSciences Inc
  • Corcept Therapeutics Inc
  • Cotinga Pharmaceuticals Inc
  • CPL Biologicals Pvt Ltd
  • CrystalGenomics Inc
  • CTI BioPharma Corp
  • Cyclacel Pharmaceuticals Inc
  • CytImmune Sciences Inc
  • Cytori Therapeutics Inc
  • CyTuVax BV
  • Daiichi Sankyo Co Ltd
  • DEKK-TEC Inc
  • Delta-Fly Pharma Inc
  • Denceptor Therapeutics Ltd
  • Diffusion Pharmaceuticals Inc
  • Eisai Co Ltd
  • Eleison Pharmaceuticals LLC
  • Eli Lilly and Co
  • Endor Technologies SL
  • Enterome Bioscience SA
  • Erytech Pharma SA
  • Esperance Pharmaceuticals Inc
  • Etubics Corp
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • Felicitex Therapeutics Inc
  • FibroGen Inc
  • Forbius
  • Formosa Laboratories Inc
Note: Product cover images may vary from those shown
Adroll
adroll